Alpha Wave Global LP Buys Shares of 72,407 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Alpha Wave Global LP bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 72,407 shares of the medical equipment provider's stock, valued at approximately $6,478,000. Lantheus accounts for about 3.0% of Alpha Wave Global LP's investment portfolio, making the stock its 6th biggest holding. Alpha Wave Global LP owned about 0.10% of Lantheus as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC acquired a new stake in Lantheus during the fourth quarter worth about $27,000. Summit Securities Group LLC purchased a new position in shares of Lantheus in the 4th quarter worth about $37,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC purchased a new stake in shares of Lantheus during the 3rd quarter worth about $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,109 shares of company stock worth $6,016,046. 2.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

LNTH has been the subject of several research reports. JMP Securities reiterated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded up $2.66 during midday trading on Wednesday, reaching $102.23. The company had a trading volume of 185,414 shares, compared to its average volume of 950,835. Lantheus Holdings, Inc. has a one year low of $62.59 and a one year high of $126.89. The stock has a market capitalization of $7.00 billion, a P/E ratio of 17.01 and a beta of 0.20. The stock's fifty day moving average price is $96.11 and its 200-day moving average price is $95.36.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.